Another limitation to point out is the difference in median follow\up durations for each FISH probe. considered statistically significant. Results Patient characteristics The baseline patient characteristics of the 565 individuals are demonstrated in Table?1. The median age was 63?years (18C92?years), and TAS-103 there were 309 males (54.7%). The proportion of individuals at International Staging System (ISS) stage III was 32.4%, while those at Revised International Staging System TAS-103 (R\ISS) stage III was 50.1%. Among the enrolled individuals, 42.7% underwent autoSCT. For those undergoing autoSCT, the most common induction therapy used was thalidomide centered (128/241, 53.1%), followed by cytotoxic chemotherapy based (77/241, 32.9%). Bortezomib\centered induction was used in 46 individuals (19.1%), and none received lenalidomide while induction for autoSCT (Table?1 and Fig.?1). All the individuals receiving standard TAS-103 chemotherapy as 1st\collection treatment were consequently exposed to either proteasome inhibitors and/or IMiDs in subsequent treatments. Table 1 Baseline characteristics of 565 enrolled individuals (%) /th /thead Age?Median (years, range)63 (18C92)? 65?years317 (56.1)?65?years248 (43.9)Sex?Male309 (54.7)Performance status?ECOG 0C1307 (54.4)?ECOG 2252 (44.6)?Missing6 (1.0)Ig type?IgG / A / Others276 (48.8) / 102 (18.1) / 23 (4.0)?Light chain164 (29.0)Light chain?Kappa / Lambda304 TAS-103 (53.8) / 261 (46.2)?Missing0ISS?I/II/III155 (27.5) /190 (33.6) /183 (32.4)?Missing37 (6.5)R\ISS?I/II/III39 (6.9) / 251 (38.1) / 283 (50.1)?Missing28 (5.0)Azotemia at MM analysis?Creatinine 2?mg/dL104 (18.4)?Creatinine 2?mg/dL461 (81.6)Treatment?autoSCT241 (42.7)?Thalidomide exposure322 (57.0)?Bortezomib exposure398 (70.4)1st line150Second line and beyond248?Lenalidomide exposure145 (25.7)1st line8Second line24Third line and beyond113 Open in a separate window ECOG, Eastern Cooperative Oncology Group; DSS, DurieCSalmon staging; ISS, International Staging System; R\ISS, Revised International Staging System; Rabbit polyclonal to HIRIP3 MM, multiple myeloma; SD, standard deviation; autoSCT, autologous stem cell transplantation. Standard cytogenetics and FISH abnormalities The rate of recurrence of each FISH panel used assorted (Table?2). IgH rearrangement was tested most often (520/565, 92.0%) and em t /em (14;16) least often (326/565, 57.7%). Overall, there were 277 (49.0%) individuals with all seven FISH panels. FISH results showed del(17p13) in 8.8% (29/331), del(13q14) in 35.5% (184/519), em t /em (14;16) in 2.5% (8/326), em t /em (4;14) in 27.9% (109/390), IgH rearrangement in 47.7% (248/520), trisomy 1q21 in 40.8% (211/517), and del(9p21) in 2.2% (11/505) of instances. Table 2 FISH abnormalities thead valign=”top” th align=”remaining” rowspan=”2″ valign=”top” colspan=”1″ /th th align=”remaining” rowspan=”2″ valign=”top” colspan=”1″ Tested /th th align=”remaining” rowspan=”2″ valign=”top” colspan=”1″ Positive (%) /th th align=”remaining” rowspan=”2″ valign=”top” colspan=”1″ Alone (%) /th th align=”remaining” colspan=”3″ style=”border-bottom:solid 1px #000000″ valign=”top” rowspan=”1″ Combination (%) /th th align=”remaining” valign=”top” rowspan=”1″ colspan=”1″ Two /th th align=”remaining” valign=”top” rowspan=”1″ colspan=”1″ Three /th th align=”remaining” valign=”top” rowspan=”1″ colspan=”1″ Four or more /th /thead del(17p13)33129 (8.8)7 (24.1)3 (10.3)4 (13.8)15 (51.7)del(13q14)519184 (35.5)19 (10.3)59 (32.1)72 (39.1)34 (18.5) em t /em (14;16)3268 (2.5)1 (12.5)1 (12.5)2 (25.0)4 (50.0) em t /em (4;14)390109 (27.9)63 (25.4)2 (1.8)19 (17.4)25 (23.0)IgH rearrange520248 (47.7)68 (27.4)66 (26.6)79 (31.9)35 (14.1)+1q21517211 (40.8)42 (19.9)66 (31.3)70 (33.2)33 (15.6)del(9p21)50511 (2.2)5 (45.5)1 (9.1)3 (27.3)2 (18.2) Open in a separate windowpane TAS-103 FISH, fluorescence in situ hybridization; IgH rearrange, IgH rearrangement. FISH abnormalities and treatment response Table?3 and Number?2 represent treatment response to bortezomib and lenalidomide, regardless of treatment timing, according to different FISH status. The presence of del(17p13) seemed to decrease bortezomib response (Table?3), but the difference did not reach statistical significance. However, the presence of del(17p13) was associated with shorter PFS to bortezomib (median PFS 27?weeks for del(17p13)\negative group versus 9?weeks for del(17p13)\positive group, em P? /em = em ? /em 0.011) (Fig.?2A). Lenalidomide response was not altered relating to del(17p13) status. The presence of del(17p13) was associated with shorter PFS to autoSCT (median PFS 28?weeks for del(17p13)\negative group vs. 11?weeks for del(17p13)\positive group, em P? /em = em ? /em 0.024). Open in a separate window Number 2 Progression\free survival (PFS) after bortezomib, lenalidomide treatment, and autologous.